Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
- Regulatory Reform Council Gives Directions for Expansion of Special Scheme for Mixed Healthcare, Yet No Concrete Plan
December 26, 2013
- Health Ministry Committee Decides Details of Drug Safety Evaluation after Rx-to-OTC Switches
December 26, 2013
- FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
- Government to Allocate 8,696 Million Yen in FY2014 Budget for Faster Drug Review, Pharma Business Revitalization
December 25, 2013
- FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
- MHLW Will Level Charges against Novartis, If Necessary: Minister
December 24, 2013
- Premium for Innovativeness or Usefulness (I) Set as Prerequisite for 10% “Precursor Premium”
December 20, 2013
- Generic Share Fails to Meet FY2012 Target but Reaches 47% in New Calculation Method
December 20, 2013
- Chuikyo’s DPC Subcommittee Continues to Support Original Proposal on Generic Drug Index; Will Report Accordingly at Upcoming General Meeting
December 20, 2013
- PhRMA Japan Head, Other Observers Invited for Comments for First Time at Health Ministry Vaccination Panel
December 20, 2013
- Vaccine Dose Intervals to Become More Flexible Starting Next April
December 20, 2013
- Plan to “Institutionalize” Key Premium Ditched for FY2014 Revision; Status Quo to Remain
December 19, 2013
- Chuikyo Subcommittee Agrees on 60% Rule for First Generic Prices, 70% for Biosimilars
December 19, 2013
- Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
- “COI Management” to Be Specified in Unified Ethics Code for Epidemiological, Clinical Research
December 18, 2013
- Japan NIH to Be Staffed with 100-Plus Employees from 6 Govt Organizations
December 18, 2013
- MHLW Boots Up Project Team to Spur Clinical Application of Novel Drugs; Paper Due Out in April
December 17, 2013
- Japan Govt OKs Basic Policy for FY2014 Budget; Wording Tweaked in Favor of Healthcare Circles
December 17, 2013
- Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…